As a new-type foreign trade service provider driven by technological transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply chondroitin sulfate sourced directly from multiple well-known original manufacturers. Endowed with R&D capabilities, HiSiaddi has repeatedly resolved customized chondroitin sulfate requirements for clients through technological transformation cooperation with manufacturers and precise insight into market demands. Below is a case in which HiSiaddi delivered a customized chondroitin sulfate product as requested by a client.
Should you require customized service support, please contact HiSiaddi customer service.
The cooperating buyer is ORTHOLIFE, a health group based in California, U.S.A. For 32 years, it has focused on high-end medical dietary supplements for bone and joint health and special medical raw materials for sports rehabilitation across North America. Its products are sold in premium lines of CVS, a major U.S. pharmacy chain, supplied to team physicians of top North American professional basketball and rugby leagues, and listed as raw materials for in-hospital preparations in U.S. rehabilitation hospitals. All its products comply with the United States Pharmacopeia (USP), FDA dietary raw material access standards, NSF factory certification, California food raw material control acts, and TSE/BSE bovine spongiform encephalopathy control specifications. The group mainly produces three types of finished products: high-end sustained-release tablets, enteric-coated softgels, and joint repair oral liquids, and only adopts refined customized chondroitin sulfate as raw materials. It is a typical high-quality mid-to-high-end client, distinct from low-end trading buyers that mass-produce low-cost products for generic supermarkets.
For the previous 12 years, the group sourced customized shark-derived chondroitin sulfate exclusively from European pharmaceutical manufacturers, with an annual stable purchase volume of 41 tons. However, multiple adverse factors including shrinking local raw material production capacity in Europe, tightened quotas for marine shark raw materials, a cumulative 31% year-on-year surge in raw material prices, a raised minimum order quantity of 8 tons for customized products, and an extended ocean delivery cycle of 110 days prompted the group to launch a localization substitution project for Chinese-sourced raw materials in 2025. The client brought five exclusive mandatory customized indicators to four leading domestic chondroitin sulfate manufacturers (Shandong Wantuming, Shandong Guanghao, Zhejiang Aoxing, Shandong Xinyuhui) for sample trials one by one. All four manufacturers mainly produced standardized mass-produced models and could only slightly adjust conventional indicators instead of conducting targeted process modification and customized production in accordance with the client’s exclusive parameters. Eight consecutive rounds of sample testing all failed to meet the requirements of the finished product formula, stalling the customization project and delaying the new product launch plan. The daily loss caused by suspended R&D exceeded USD 3,200. With domestic manufacturers unable to fulfill the customized requirements, the client fully entrusted HiSiaddi, a foreign trade service provider, to coordinate formula decomposition, factory screening, process customization, pilot mass production, and full-chain implementation, delivering customized exclusive-grade chondroitin sulfate relying on China’s domestic biological extraction industrial chain resources.
1. Raw material source: Extracted from deep-sea Arctic gray shark cartilage; terrestrial animal-derived raw materials (bovine, porcine, chicken) are rejected to avoid TSE/BSE epidemic prevention risks and terrestrial allergen hazards;
2. Customized molecular weight: Weight-average molecular weight controlled at 18,000 Da ±1,200 Da with a molecular weight distribution coefficient ≤1.5 (general commercial products commonly range from 30,000 to 50,000 Da with a distribution coefficient above 1.8), compatible with targeted intestinal absorption of enteric-coated capsules;
3. Active ingredient content: HPLC-determined dry basis chondroitin sulfate content ≥96.5% (national standard qualified products require ≥90%, while mainstream mass-produced products reach only 92%–94%); 4S/6S sulfated disaccharide ratio fixed at 1.3±0.05, strictly complying with high-end grade standards of USP43;
4. Impurity control: Free protein residue ≤0.7%, total heavy metals (lead, arsenic, cadmium) <8 ppm, chloride ion ≤0.3%, far stricter than limits specified in national standards and ordinary export food-grade products;
5. Customized physical powder properties: 120-mesh full pass sieve, repose angle 31°±1°, low moisture absorption characteristic with moisture absorption weight gain <1.1% after 72 hours under 65% humidity, suitable for automated dry powder blending and wet feeding of softgel production processes.
All four leading manufacturers possess mass production qualifications, conventional USP-grade production capacity, and GMP clean workshops, yet their production lines are built around mass-produced standard food-grade and general pharmacopoeia-grade products with fixed equipment, enzymatic hydrolysis, and purification processes – this constitutes the core bottleneck hindering customized production, manifested in four major challenges:
Shandong Guanghao and Xinyuhui rely mainly on duck bone and bovine trachea cartilage for their core production lines, with only a small reserve of mixed-source shark raw materials unavailable for stable bulk procurement of compliant Arctic gray shark cartilage. While Wantuming and Aoxing stock marine-derived raw materials, they regularly source offshore shark cartilage from Southeast Asia, whose inherent sulfation ratio and natural molecular weight differ drastically from Arctic gray shark cartilage. The manufacturers lack dedicated raw material sorting and targeted pre-treatment sections and refuse to separately procure exclusive raw materials for small-batch customization, as standalone raw material procurement costs far exceed the client’s budget.
Mass-produced chondroitin sulfate available commercially adopts fixed temperature and fixed enzyme dosage for batch enzymatic hydrolysis, yielding products with broad molecular weight ranges. Locking the narrow target molecular weight window of 18,000 Da requires splitting the original continuous production line and adding segmented controllable low-temperature enzymatic hydrolysis reactors and multi-stage membrane separation purification equipment. The four manufacturers operate continuous assembly lines; production line shutdown for modification would incur heavy losses, so they are unwilling to alter mass production processes for niche single-client customization. They can only conduct minor post-production sieving adjustments, failing to achieve precise molecular weight control. Molecular weight fluctuation reached a maximum of 7,000 Da across the first eight sample batches, leading to unqualified capsule disintegration and absorption indicators.
General products are eligible for factory release with internal control free protein standards ≤2.5%, while the client’s customized requirement of ≤0.7% demands additional three rounds of resin adsorption refining and low-temperature alcohol precipitation purification procedures. The conventional refining sections of the four manufacturers only implement two-stage purification without supporting deep impurity removal equipment. Extra purification would drastically extend production cycles and raise manufacturing costs, pushing routine manufacturer quotations 27% above the client’s budget, creating unresolvable pricing discrepancies.
Standard drying and crushing equipment used by manufacturers yields uneven powder with excessive fine particles and a universal repose angle of 36°–42% alongside high moisture absorption. The material tends to agglomerate and block pipelines during the client’s automated feeding process. Manufacturers lack air flow classification modification equipment to directionally adjust physical powder indicators, resulting in stratification and wall adhesion scrapping during the client’s pilot blending of samples.
Unified business logic shared by all four manufacturers: prioritize promoting mature mass-produced in-house models, persuade clients to relax customized indicators and switch to low-cost terrestrial raw materials to cut production costs, and refuse to invest in technical renovations for niche customization. This led to eight failed sample batches and a shrinking window for new product launch.
HiSiaddi assembled a dedicated project team consisting of raw material procurement specialists, biological process engineers, on-site factory technical renovation specialists, and compliance document specialists. Leveraging domestic cartilage raw material resources and flexible OEM production line resources, the team delivered end-to-end customization following the workflow: secure exclusive raw materials → screen flexible customized OEM factories → optimize production processes in segments → conduct lab-scale verification → launch mass production.
HiSiaddi partnered with domestic specialized importers of deep-sea aquatic raw materials to secure clean Arctic gray shark cartilage imported from Norway. Each batch is accompanied by Norwegian fishery fishing traceability certificates, raw material microbial quarantine reports, and marine heavy metal test certificates. Monthly fixed-price stock reservations eliminate risks of mixed raw material sources and adulteration with terrestrial raw materials, ensuring the raw material base meets customized indicators from the source. Synchronized phased delivery of raw materials to OEM plants reduces raw material storage losses for manufacturers.
Shandong Wantuming Biological was selected as the customized OEM manufacturer from the four factories; it features an independent flexible pilot workshop with modular small-scale enzymatic hydrolysis and purification equipment distinct from continuous mass production assembly lines, alongside experience in USP pharmacopoeia-grade customized renovation. HiSiaddi collaborated with the factory’s technical department to split all customized production stages and implement targeted partial renovations to the pilot production line:
1. Install 5 sets of segmented temperature-controlled low-temperature enzymatic hydrolysis reactors to precisely regulate cartilage enzymatic hydrolysis rates in phases, cutting polysaccharide chains with controllable enzyme activity to lock target molecular weight;
2. Equip nanofiltration molecular weight classification membrane separation systems to intercept and separate oversized and undersized molecular fragments, strictly limiting the distribution coefficient to ≤1.5;
3. Add three-stage macroporous adsorption resin deep impurity removal sections to sequentially remove free protein, residual inorganic salts, and heavy metal impurities to achieve the stringent ≤0.7% protein standard;
4. Deploy air flow crushing + classification sieving equipment for directional powder modification post-drying to precisely control mesh size, repose angle, and moisture absorption indicators. HiSiaddi coordinated and shared technical renovation investment costs, adopting mass production cost amortization to avoid excessive raw material quotations for one-off customization.
1. Lab-scale trials (3 batches, 500g per batch): Fine-tune enzymatic hydrolysis temperature, enzyme addition ratio, and alcohol precipitation concentration item by item, continuously testing content, sulfation ratio, and molecular weight via HPLC to optimize process parameters;
2. Pilot trial production (3 batches, 80kg per batch): Simulate full mass production workflows for complete batches, send samples to the client’s U.S. laboratory for full-item testing simultaneously, and adjust drying temperature and modified auxiliary dosage based on powder moisture absorption. After three rounds of pilot production, all indicators fully complied with customized specifications, prompting the client’s R&D department to issue a sample qualification confirmation letter.
Total annual customized volume stands at 41 tons, split into 8 monthly flexible production batches with a minimum single-batch order of 3.8 tons matching the pilot workshop’s production capacity, eliminating risks of process fluctuations from one-time large-batch manufacturing. HiSiaddi maintained full-time on-site factory supervision, sampling twice per batch (mid-production and pre-delivery) for full-item USP-standard testing at SGS third-party laboratories, issuing bilingual Chinese-English Certificates of Analysis (COA).
Food-grade moisture-proof inner bags + cardboard drum outer packaging were customized in compliance with U.S. FDA import requirements. English labels on drums adhere to FDA raw material labeling standards, marking raw material source, CAS number, USP grade, batch number, and storage conditions. Supporting documents including TSE/BSE terrestrial-source-free declarations, notarized NSF factory certifications, certificates of origin, and FDA raw material filing materials were compiled to meet U.S. customs clearance and client incoming inspection standards.
The first 5.2-ton batch of customized chondroitin sulfate was shipped from Qingdao Port to Los Angeles Port, U.S.A. The complete set of testing and compliance documents passed U.S. FDA entry sampling inspection and the client’s full-item incoming re-inspection in one go, with all customized indicators reaching standards. The client immediately launched full-scale mass production across three high-end formulation lines, releasing the new product onto the North American market as scheduled, three months ahead of the original delayed timeline. The remaining 35.8 tons were shipped sequentially across seven subsequent batches, with all 41 tons of annual customized raw materials delivered smoothly without batch indicator overruns or cargo detention at customs.
Cost performance: Compared with raw materials previously imported from Europe, the client’s comprehensive procurement cost dropped by 26.3%, and ocean delivery cycles were shortened from 110 days to 39 days, drastically improving supply chain turnover efficiency.
1. ORTHOLIFE Group of the U.S.A. fully terminated procurement from European manufacturers, shifting 100% of its annual 41-ton chondroitin sulfate sourcing to HiSiaddi’s customized domestic supply. A new 16-ton annual customized order for fermented vegetarian chondroitin sulfate was added in 2026 for the group’s new vegetarian joint oral liquid product line;
2. The client’s Canadian subsidiary, a high-end sports nutrition brand, initiated a new project leveraging process experience accumulated in this customization case, locking in pre-set customized parameters and adding a supplementary annual procurement volume of 12 tons;
3. Drawing on customized process insights from this project, HiSiaddi assisted cooperating manufacturers in formalizing standardized customized processes for shark-derived high-end chondroitin sulfate, successfully securing customized demand from two peer mid-to-high-end nutrition brands in Canada and Germany.
Most domestic chondroitin sulfate manufacturers focus on standardized mass production, with production lines and processes built around general-grade products. Driven by production costs and production line shutdown losses, manufacturers are reluctant to invest in technical renovations for niche exclusive specifications required by overseas mid-to-high-end clients. Mid-to-high-end European and American medical food enterprises feature proprietary formulas with highly customized raw material indicators; standardized mass-produced raw materials available on the market fail to match formulation requirements, and independent manufacturer engagement often leads to repeated failed sample trials and stalled customization projects. Breaking the traditional foreign trade model limited to intermediate supply, HiSiaddi centers full-chain technical services, coordinating raw material traceability, flexible factory screening, technical process renovation, sample testing control, and compliance supporting across all links. It bridges the adaptation gap between precise customized domestic raw materials and high-end overseas formulas, enabling North American mid-to-high-end clients to smoothly complete domestic raw material substitution, cut procurement costs, and guarantee new product launch schedules, while helping premium domestic biomanufacturers break free from homogenized low-price competition and enter global high-end medical food raw material supply chains – delivering long-term win-win outcomes for both supply and demand sides.
Should you require customized service support, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
